Device Firms Expect Little From Obamacare Insurance Expansion, But Numbers More Complicated
This article was originally published in The Gray Sheet
Executive Summary
It remains to be seen how many new people end up insured on the Obamacare exchanges, and what the impact will be on device markets. Many executives at implantable companies suggest they will see almost no impact, in part because they get most of their business from Medicare. Government health care statistics, actually suggest a fairly high percentage of under-65-year-old patients get pacemakers, stents, knees and other devices. But there may also be other factors at play.